Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

THRD - Third Harmonic Bio, Inc.


IEX Last Trade
10.23
-0.020   -0.196%

Share volume: 2,630
Last Updated: Fri 27 Dec 2024 08:20:32 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$10.25
-0.02
-0.20%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0.28%
1 Month
-17.39%
3 Months
-19.78%
6 Months
-15.52%
1 Year
-5.58%
2 Year
159.71%
Key data
Stock price
$10.23
P/E Ratio 
0.00
DAY RANGE
$10.12 - $10.80
EPS 
$0.00
52 WEEK RANGE
$8.78 - $16.69
52 WEEK CHANGE
-$1.28
MARKET CAP 
474.676 M
YIELD 
N/A
SHARES OUTSTANDING 
41.098 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$177,555
AVERAGE 30 VOLUME 
$239,357
Company detail
CEO: Natalie C. Holles
Region: US
Website: thirdharmonicbio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

We are a clinical-stage biopharmaceutical company focused on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. Our principal executive offices are located at 300 Technology Square, 8th Floor, Cambridge, Massachusetts.

Recent news